Pitavastatin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Pitavastatin
- Pitavastatin: From Familial Combined Hyperlipidaemia to Homozygous Familial Hypercholesterolaemia
Pitavastatin: From Familial Combined Hyperlipidaemia to Homozygous Familial Hypercholesterolaemia
One-Sentence Summary
Pitavastatin is a statin (HMG-CoA reductase inhibitor) originally used to treat familial combined hyperlipidaemia. The TxGNN model predicts it may be effective for homozygous familial hypercholesterolaemia (HoFH), but there are no registered clinical trials and only 2 publications (one RCT in HIV-associated dyslipidaemia and one case report), so the evidence is indirect and weak.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Familial combined hyperlipidaemia (from the knowledge graph; the Singapore licence records contain no approved indication text) |
| Predicted New Indication | Homozygous familial hypercholesterolaemia |
| TxGNN Prediction Score | 99.996% |
| Evidence Level | L5 on the strict rule (no trials; the one RCT is in a different population). The compiled data grades this indication L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, pitavastatin inhibits HMG-CoA reductase, which lowers intracellular cholesterol and upregulates hepatic LDL receptors, increasing LDL-C clearance.
Familial combined hyperlipidaemia and familial hypercholesterolaemia are both inherited disorders of lipid metabolism, so the model's link is biologically plausible. However, HoFH patients usually carry null or defective LDL receptor variants. Statins depend on residual receptor activity, so response is expected to be limited and variable.
The only supportive item is a 2025 case report of rapid lipid lowering in autosomal recessive hypercholesterolaemia (LDLRAP1), a condition clinically similar to HoFH. This is indirect evidence only.
Related predictions in the same analysis:
- Hyperlipoproteinaemia (rank 2) is effectively an on-label use, supported by Phase 3 and Phase 4 RCTs (see below).
- Familial hypercholesterolaemia (rank 3) and autosomal dominant hypercholesterolaemia (rank 5) are supported by paediatric clinical studies in Japan and Europe.
- HIV infection (rank 7) concerns cardiovascular risk reduction in people with HIV (the REPRIEVE trial), not treatment of the infection.
Clinical Trial Evidence
Currently no related clinical trials are registered for homozygous familial hypercholesterolaemia.
For the closely related indication hyperlipoproteinaemia, the following trials were found:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01386853 | Phase 3 | Unknown | 200 | Double-blind, non-inferiority comparison of pitavastatin vs atorvastatin in high-risk hypercholesterolaemia (12 weeks) |
| NCT01256476 | Phase 4 | Completed | 328 | Double-blind comparison of pitavastatin 4 mg vs pravastatin 40 mg in primary hyperlipidaemia or mixed dyslipidaemia |
| NCT01166633 | Phase 4 | Completed | 200 | Dose-titration study of pitavastatin vs atorvastatin in hypercholesterolaemia with mild to moderate hepatic damage |
| NCT02056847 | Phase 4 | Completed | 313 | Open-label study of pitavastatin 2 mg vs 4 mg on HbA1c in hyperlipidaemia with impaired fasting glucose |
| NCT00711919 | NA | Unknown | 300 | Atherosclerosis regression (carotid IMT) with intensive vs conventional lipid lowering |
| NCT01695954 | Phase 1 | Completed | 34 | Pharmacokinetic interaction with efavirenz and darunavir/ritonavir |
Literature Evidence
Directly relevant to the predicted indication (HoFH):
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28416195 | 2017 | RCT | The Lancet HIV | Pitavastatin vs pravastatin in adults with HIV and dyslipidaemia; pitavastatin avoids cytochrome P450 metabolism. Not an HoFH population |
| 39532566 | 2025 | Case report | Journal of Clinical Lipidology | Rapid lipid-lowering response in two cases of autosomal recessive hypercholesterolaemia (LDLRAP1), clinically similar to HoFH |
Supporting evidence from related familial hypercholesterolaemia indications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25891210 | 2016 | Clinical trial | J Atheroscler Thromb | Efficacy and safety of pitavastatin in Japanese boys with heterozygous FH |
| 29187694 | 2018 | Clinical trial | J Atheroscler Thromb | Pitavastatin in children and adolescents with FH, Japan and Europe compared |
| 23672789 | 2013 | RCT | Journal of Cardiology | Pitavastatin vs atorvastatin on HDL-C and adiponectin in dyslipidaemia with coronary disease (COMPACT-CAD) |
| 37486775 | 2023 | RCT | NEJM | REPRIEVE: pitavastatin to prevent cardiovascular disease in HIV infection |
| 17957184 | 2008 | Crossover study | Clin Pharmacol Ther | Pitavastatin and atorvastatin gave comparable LDL-C reductions (about 41–43%) in 19 patients with heterozygous FH |
| 12048134 | 2002 | Long-term study | Atherosclerosis | Total cholesterol fell by 31% over up to 104 weeks in 25 patients with heterozygous FH |
| 41036155 | 2025 | Case report | Clinical Case Reports | Two children with heterozygous FH managed with pitavastatin plus ezetimibe |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN15859P | LIVALO Film-Coated Tablets 2 mg (Kowa Company, Ltd.) | Film-coated tablet | Not recorded |
| SIN15860P | LIVALO Film-Coated Tablets 4 mg (Kowa Company, Ltd.) | Film-coated tablet | Not recorded |
Safety Considerations
- Contraindications suggested by the knowledge graph (not label text): liver disease, gallbladder disease, hypothyroidism (including myxedema and congenital hypothyroidism), myopathy and other muscle diseases, familial periodic paralysis, hypotensive disorder, rhabdomyolysis, impaired renal function and injury.
- Drug Interactions: 86 interactions are recorded. The most important is erythromycin (Major). Moderate interactions include other statins (rosuvastatin, simvastatin), cobicistat, eltrombopag, chloroquine and hydroxychloroquine, metronidazole and tinidazole, disulfiram, naltrexone, eluxadoline, zafirlukast, chloramphenicol, dapsone and ethanol. Warfarin and dicoumarol are Minor.
- For the full set of warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: For homozygous familial hypercholesterolaemia, the prediction score is very high, but there are no registered trials and the only supporting items are an RCT in an HIV population and a small case report. HoFH patients often have little residual LDL receptor activity, so statin response may be limited. The better-supported directions are related indications (hyperlipoproteinaemia and heterozygous FH), where pitavastatin is largely already used within its approved lipid-lowering role.
To proceed, the following is needed:
- Clinical data in genetically confirmed HoFH, with stratification by LDL receptor residual activity
- Detailed mechanism of action data
- Package insert warnings and contraindications from the Singapore regulator (HSA), plus the approved indication text for the two licences
- A safety plan covering myopathy, liver effects and interactions (especially erythromycin and other CYP or transporter-related drugs)
- A review of whether the more strongly supported indications (heterozygous FH, and cardiovascular prevention in HIV) are better candidates, which would likely carry a "Proceed with Guardrails" decision
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.